Wednesday, December 2, 2020

On the Record 12 02 2020

"The way in which it could be somewhat bad for PBMs is pretty indirect. It's the idea that Amazon is now going to be showing every Prime customer two prices for every pharmacy transaction…it's really going to highlight the disparities of the cost to you of any given drug if you use insurance or if you choose not to use insurance."

— SVB Leerink analyst Stephen Tanal talked with AIS's RADAR on Drug Benefits about whether the launch of Amazon Pharmacy will pose a threat to the PBM business model.

 

Subscribers may read the RADAR on Drug Benefits article in which this quote appeared online. Learn more about subscribing to AIS Health's publications.

No comments:

Post a Comment